Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver

Molecular Therapy

Volumn 17, Issue 4, 2009, Pages 675-684

  Di Paolo, Nelson C ^a   van Rooijen, Nico ^b   Shayakhmetov, Dmitry M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CLODRONIC ACID; LIPOSOME; WARFARIN;

ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DRUG MECHANISM; GENE MUTATION; HEPATITIS; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; KUPFFER CELL; LIPOSOMAL DELIVERY; LIVER CLEARANCE; LIVER FUNCTION; LIVER TOXICITY; MOUSE; NONHUMAN; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS PARTICLE; VIRUS TRANSMISSION;

ADENOVIRIDAE; ANIMALS; BLOOD-BORNE PATHOGENS; CAPSID PROTEINS; FACTOR X; HUMANS; KUPFFER CELLS; LIVER; MICE; MUTATION; OLIGOPEPTIDES; PROTEIN BINDING; TRANSDUCTION, GENETIC; VIRAL PROTEINS;

ADENOVIRIDAE; HUMAN ADENOVIRUS; MIRIDAE;

EID: 63949088129     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.307     Document Type: Article

References (50)

1. Thomas, CE, Ehrhardt, A and Kay, MA (2003). Progress and problems with the use of viral vectors for gene therapy. Nat Rev Gen 4: 346-358.
2. Alemany, R, Suzuki, K and Curiel, DT (2000). Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81: 2605-2609.
3. Worgall, S, Wolff, G, Falck-Pedersen, E and Crystal, RG (1997). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8: 37-44.
4. Bergelson, JM, Cunningham, JA, Droguett, G, Kurt-Jones, EA, Krithivas, A, Hong, JS et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
5. Gaggar, A, Shayakhmetov, D and Lieber, A (2003). CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412.
6. Roelvink, PW, Mi Lee, G, Einfeld, DA, Kovesdi, I and Wickham, TJ (1999). Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 286: 1568-1571.
7. Segerman, A, Atkinson, JP, Marttila, M, Dennerquist, V, Wadell, G and Arnberg, N (2003). Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 77: 9183-9191.
8. Wickham, TJ, Mathias, P, Cheresh, DA and Nemerow, GR (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319.
9. Suomalainen, M, Nakano, MY Boucke, K Keller, S and Greber, UF (2001). Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus. EMBO J 20: 1310-1319.
10. Stupack, ELD, Bokoch, GM and Nemerow, GR (1998). Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. J Virol 72: 8806-8812.
11. Meier, O and Greber, UF (2003). Adenovirus endocytosis. J Gene Med 5: 451-462.
12. Nemerow, GR and Stewart, PL (1999). Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev 63: 725-734.
13. Fechner, H, Haack, A, Wang, H, Wang, X, Eizema, K, Pauschinger, M et al. (1999). Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 6: 1520-1535.
14. Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 78: 5368-5381.
15. Lieber, A, He, CY, Meuse, L, Schowalter, D, Kirillova, I, Winther, B et al. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807.
16. Tao, N, Gao, GP, Parr, M, Johnston, J, Baradet, T, Wilson, JM et al. (2001). Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3 28-35.
17. Schiedner, G, Hertel, S, Johnston, M, Dries, V, van Rooijen, N and Kochanek, S (2003). Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 7: 35-43.
18. Wolff, G, Worgall, S, van Rooijen, N, Song, WR, Harvey, BG and Crystal, RG (1997). Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 71: 624-629.
19. Ziegler, RJ, Li, C, Cherry, M, Zhu, YX, Hempel, D, van Rooijen, N et al. (2002). Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther 13: 935-945.
20. Shayakhmetov, DM, Gaggar, A, Ni, SH, Li, ZY and Lieber, A (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79: 7478-7491.
21. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488.
22. Waddington, SN, Mcvey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
23. Waddington, SN, Parker, AL, Havenga, M, Nicklin, SA, Buckley, SMK, Mcvey, JH et al. (2007). Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol 81: 9568-9571.
24. Nakamura, T, Sato, K and Hamada, H (2003). Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J Virol 77: 2512-2521.
25. Nicol, CG, Graham, D, Miller, WH, White, SJ, Smith, TAG and Nicklin, SA et al. (2004). Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 10: 344-354.
26. Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2002). Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 62: 1063-1068.
27. Smith, TA, Idamakanti, N, Rollence, ML, Marshall-Neff, J, Kim, J, Mulgrew, K et al. (2003). Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 14: 777-787.
28. Vigne, E, Dedieu, JF, Brie, A, Gillardeaux, A, Briot, D, Benihoud, K et al. (2003). Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther 10: 153-162.
29. Parker, AL, Waddington, SN, Nicol, CG, Shayakhmetov, DM, Buckley, SM, Denby, L et al. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108: 2554-2561.
30. Campos, SK and Barry, MA (2006). Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 349: 453-462.
31. Smith, JS, Xu, Z and Byrnes, AP (2008). A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. J Virol Methods 147: 54-60.
32. Haisma, HJ, Kamps, JA, Kamps, GK and Bellu, AR (2007). Poly I prevents adenoviral vector clearance by Kupffer cells and increases efficiency in gene therapy applications. Hum Gene Ther 18: 981-982.
33. Xu, Z, Tian, J, Smith, JS and Byrnes, AP (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 82: 11705-11713.
34. van Rooijen, N and van Kesteren-Hendrikx, E (2003). "In vivo" depletion of macrophages by liposome-mediated "suicide". Methods Enzymol 373: 3-16.
35. Davison, E, Diaz, RM, Hart, IR, Santis, G and Marshall, JF (1997). Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J Virol 71: 6204-6207.
36. Huang, S, Kamata, T, Takada, Y, Ruggeri, ZM and Nemerow, GR (1996). Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol 70: 4502-4508.
37. Shayakhmetov, DM, Eberly, AM, Li, ZY and Lieber, A (2005). Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol 79: 1053-1061.
38. Mizuguchi, H, Koizumi, N, Hosono, T, Ishii-Watabe, A, Uchida, E, Utoguchi, N et al. (2002). CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther 9: 769-776.
39. Smith, T, Idamakanti, N, Kylefjord, H, Rollence, M, King, L, Kaloss, M et al. (2002). In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 5: 770-779.
40. Liu, Q, Zaiss, AK, Colarusso, P, Patel, K, Haljan, G, Wickham, TJ et al. (2003). The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 14: 627-643.
41. Schiedner, G, Bloch, W, Hertel, S, Johnston, M, Molojavyi, A, Dries, V et al. (2003). A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 14: 1631-1641.
42. Schnell, MA, Zhang, Y, Tazelaar, J, Gao, GP, Yu, QC, Qian, R et al. (2001). Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 3 708-722.
43. Manickan, E, Smith, JS, Tian, J, Eggerman, TL, Lozier, JN, Muller, J et al. (2006). Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther 13: 108-117.
44. Machemer, T, Engler, H, Tsai, V, Lee, S, Cannon-Carlson, S, Voloch, M et al. (2005). Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses. Mol Ther 12 254-263.
45. Shashkova, EV, Doronin, K, Senac, JS and Barry, MA (2008). Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res 68: 5896-5904.
46. Snoeys, J, Mertens, G, Lievens, J, van Berkel, T, Collen, N, Biessen, EA et al. (2006). Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer. Mol Ther 13: 98-107.
47. Wheeler, MD, Yamashina, S, Froh, M, Rusyn, I and Thurman, RG (2001). Adenoviral gene delivery can inactivate Kupffer cells: Role of oxidants in NF-kappa B activation and cytokine production. J Leukoc Biol 69: 622-630.
48. Shayakhmetov, DM, Papayannopoulou, T, Stamatoyannopoulos, G and Lieber, A (2000). Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 74: 2567-2583.
49. Shayakhmetov, DM and Lieber, A (2000). Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol 74: 10274-10286.
50. Alemany, R and Curiel, DT (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8 1347-1353.